PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry. Today, the processing of samples for mass spectrometry is usually carried out according to homemade protocols. These processes are slow, not reproducible, not robust and cannot be ... more
Start-up miRdetect receives seed financingConsortium invests seven-digit amount in serum marker for testicular cancer detection
Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a seven-figure sum in the start-up company miRdetect located in Bremen, and founded in 2016. The company founders Meike Spiekermann and Dr. Nina Winter were able to convince the investors with their novel and accurate method for diagnosing testicular cancer.
The innovative procedure developed by Meike Spiekermann and Dr. Nina Winter is used to detect testicular cancer with a novel blood test. Testicular cancer is currently the most common malignant disease in men between the ages of 20 and 45. Most excitingly, the method can also be applied for the diagnosis of other types of cancer if the correct, corresponding marker is identified.
Since 2011, Meike Spiekermann and Dr. Nina Winter have been working on the new tumor marker at the University of Bremen. From very early on, the two biologists recognised the high potential and applicability of their new discovery: “Previous markers have an accuracy of about 50 percent. With the patented diagnostic method developed by us, we can guarantee an accuracy between 90 to 95 percent,” explains Dr. Nina Winter. In order to optimize further product development, miRdetect also relies on the expertise of urologist Prof. Klaus-Peter Dieckmann, and human geneticist Dr. Gazanfer Belge, who are also both co-founders of the company.
“The excellent data on a very broad patient base are very convincing. The positive feedback from physicians from all over Europe also shows the benefits of an optimized diagnosis both for the therapy decision and for the patient,” said Senior Investment Manager Dr. Lena Krzyzak explaining the HTGF’s commitment.
- cancer diagnostics
- blood tests
- testicular cancer
From basic research straight to a digital medical product: this vision has been turned into reality by neotiv. The team headed by Chief Executive Officer Dr. Chris Rehse and dementia researcher Prof. Emrah Düzel develops user-friendly apps that are able to measure the psychological effects ... more
High-Tech Gründerfonds (HTGF) and 5 Business Angels are investing together just under 1 million euros in node.energy GmbH. The company develops software to optimize energy costs for companies with on-site power generation. The funding will be used to further develop the software and to fina ... more
- 1Merck and Rigaku Form Partnership to Develop Novel Molecular Structure Analysis Technology
- 2On-site detection of hazardous substances
- 3How Artificial Intelligence Detects Rare Diseases
- 4How to separate nanoparticles by “shape”
- 5Bioinformatics platform for the genome-based taxonomical classification of bacteria and archaea
- 6Exposing modern forgers
- 7Experimental noninvasive tool monitors effectiveness of stem cell transplantation
- 8Novel test for the earlier detection of multiple cancers
- 9Direct Observation of Giant Molecules
- 10Confocal.nl receive Dutch Academic Startup award